Pipeline
Glycostem’s pipeline has the potential to redefine standards of care across various type of cancer where there is an urgent medical need.
Therapy
Product
Indication
Cell
Development
Pre-clinical
Phase I
Phase II
Phase III
Market Introduction
Partner
oNKord®
GTA002
AML/MM
NK Cell
Phase II
2024
JP: inno.N;
KR: inno.N
oNKord®
GTA002
AML/MM
NK Cell
II
2024
JP: inno.N;
KR: inno.N
GTA002
Solid Tumors
NK Cell
Pre-clinical
TBA
Glycostem
oNKord®
GTA002
Solid Tumors
NK Cell
PRE
TBA
Glycostem
viveNK™
GTA102
Colorectal cancer
CAR-NK
Pre-clinical
TBA
Glycostem
viveNK™
GTA102
Colorectal cancer
CAR-NK
PRE
TBA
Glycostem
GTA103
Glioblastoma
CAR-NK
Pre-clinical
TBA
inno.N
viveNK™
GTA103
Glioblastoma
CAR-NK
PRE
TBA
inno.N
GTA104
Other Solid Tumors
CAR-NK
Pre-clinical
TBA
inno.N
viveNK™
GTA104
Other Solid Tumors
CAR-NK
PRE
TBA
inno.N
GTA201
N/D
TCR-NK
Development
TBA
Glycostem
viveNK™
GTA201
N/D
TCR-NK
DEV
TBA
Glycostem
Therapy
Phase
Market introduction
oNKord®
GTA002
AML/MM
NK Cell
Phase II
2024
JP: inno.N;
KR: inno.N
oNKord®
GTA002
AML/MM
NK Cell
II
2024
JP: inno.N;
KR: inno.N
GTA002
Solid Tumors
NK Cell
Pre-clinical
TBA
Glycostem
oNKord®
GTA002
Solid Tumors
NK Cell
PRE
TBA
Glycostem
viveNK™
GTA102
Colorectal cancer
CAR-NK
Pre-clinical
TBA
Glycostem
viveNK™
GTA102
Colorectal cancer
CAR-NK
PRE
TBA
Glycostem
GTA103
Glioblastoma
CAR-NK
Pre-clinical
TBA
inno.N
viveNK™
GTA103
Glioblastoma
CAR-NK
PRE
TBA
inno.N
GTA104
Other Solid Tumors
CAR-NK
Pre-clinical
TBA
inno.N
viveNK™
GTA104
Other Solid Tumors
CAR-NK
PRE
TBA
inno.N
GTA201
N/D
TCR-NK
Development
TBA
Glycostem
viveNK™
GTA201
N/D
TCR-NK
DEV
TBA
Glycostem